Search Results
Your search for ,ARE matches 21644 pages
Showing 7451 - 7500Avelumab for Patients With Gestational Trophoblastic Tumors Resistant to Single-Agent Chemotherapy
In the French phase II TROPHIMMUN trial reported in the Journal of Clinical Oncology, Benoit You, MD, PhD, and colleagues found that avelumab normalized human chorionic gonadotropin (hCG) levels in approximately half of women with gestational trophoblastic tumors resistant to single-agent...
FDA Pipeline: Designations in Kidney and Lung Cancers, Myelodysplastic Syndromes, and More
Over the past few weeks, the U.S. Food and Drug Administration (FDA) has issued designations and accepted applications for novel agents, as well as approved companion diagnostics. We summarize these regulatory movements below. Breakthrough Therapy Designation for MK-6482 in von Hippel-Lindau...
ASCO Guideline Supports Continued Use of Dexamethasone for Patients Receiving Checkpoint Inhibitors and Emetogenic Chemotherapy
The ASCO guideline on the use of antiemetics has been updated to include new anticancer agents, antiemetics, and regimens.1 The guideline also addresses a growing concern among some oncologists that corticosteroids and their immunosuppressive abilities could potentially compromise the efficacy of...
Severe Hearing Impairment Associated With Neurocognitive Deficits in Childhood Cancer Survivors
Findings from a report published by Bass et al in JAMA Oncology show that childhood cancer survivors with severe hearing loss are at a significant increased risk for neurocognitive deficits, independent of what type of therapy they receive. This study is the first to objectively measure hearing and ...
Role of TP53 Mutations on Disease Severity in Myelodysplastic Syndromes
Considered the “guardian of the genome,” TP53 is the most commonly mutated gene in patients with cancer. TP53's normal function is to detect DNA damage and prevent cells from passing this damage on to daughter cells. When TP53 is mutated, the protein made from this gene, called p53, can no longer...
ASH Annual Meeting Announced as an All-Virtual Event
The American Society of Hematology (ASH) announced its decision not to hold the 62nd ASH Annual Meeting in San Diego as planned given the continuing threat of the COVID-19 pandemic. The meeting will be offered as a virtual experience from December 5–8, 2020. The Society commented, “While there is...
Nationwide Trends Show Fewer Patients With Cancer in the United States Seeking Care Since Start of the COVID-19 Pandemic
Research published by London et al in JCO Clinical Cancer Informatics found significant decreases nationwide in the number of patients seen for cancer-related care as the COVID-19 pandemic progressed during the first few months of 2020. The most significant decline was seen in encounters related to ...
Late Morbidity and Mortality in Survivors of Childhood ALL Receiving Contemporary Risk-Stratified Therapy
In an analysis from the Childhood Cancer Survivor Study reported in the Journal of Clinical Oncology, Dixon et al found that 5-year survivors of childhood acute lymphoblastic leukemia (ALL) diagnosed and treated with risk-stratified therapy in the 1990s had reduced morbidity and health-related late ...
FDA Approves Tafasitamab-cxix Combined With Lenalidomide to Treat Adults With Relapsed/Refractory DLBCL
On July 31, the U.S. Food and Drug Administration (FDA) approved tafasitamab-cxix (Monjuvi) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)–not otherwise specified, including DLBCL arising from low-grade...
Overcoming the Challenges of Improving Psychosocial Care for Patients With Cancer
Although the United States spends billions of dollars each year on cancer research, very little of that funding is dedicated to mental health research in patients with cancer, despite the fact that cancer survivors have a six-time higher risk for psychological disability than people without...
Pan-BET Bromodomain Inhibitor Plus Enzalutamide in Advanced Prostate Cancer
A new multi-institution, dose-determining clinical trial of a compound for patients with metastatic, castration-resistant prostate cancer showed the combination “demonstrated acceptable tolerability and potential efficacy,” reported Aggarwal et al in Clinical Cancer Research. The phase Ib/IIa study ...
ESMO Issues Consensus on the Management of Patients With Cancer During the COVID-19 Pandemic
A European Society for Medical Oncology (ESMO) interdisciplinary expert consensus paper on how to manage patients with cancer during the COVID-19 pandemic was published by Giuseppe Curigliano, MD, PhD, and colleagues in Annals of Oncology. The guidance encourages medical oncologists worldwide not...
Updated ASCO Guideline Revisits Evidence on Prevention and Treatment of Chemotherapy-Induced Neuropathy
Peripheral neuropathy is one of the most prominent chronic side effects of chemotherapy and can linger for years, causing discomfort as well as impaired functionality and quality of life. Yet oncologists have struggled to identify definitive treatment and prevention strategies. In an effort to help ...
Xavier Llor, MD, PhD, on Colorectal Cancer: Why Are More Younger People Being Affected?
Xavier Llor, MD, PhD, of Yale University School of Medicine, discusses the steep rise of early-onset colorectal cancer over the past 15 years, which cannot be explained by genetic predisposition but may be prompted by environmental factors (Session ED35).
Analysis of Deep Whole-Genome Sequencing in Patients With Multiple Myeloma Identifies Superior Outcome Subgroup
In a study of genome-wide somatic alterations in multiple myeloma reported in the Journal of Clinical Oncology, Samur et al identified a subgroup of patients with superior outcomes who are not adequately identified by traditional risk markers. The study involved analysis of deep whole-genome...
Does Periodontal Disease Increase the Risk of Colorectal Cancer?
Periodontal disease was associated with an increased risk of two precursors of colorectal cancer, according to results of a study published by Lo et al in Cancer Prevention Research. “Periodontal disease is prevalent among adults, with periodontitis affecting more than 40% of the U.S. population,”...
American Cancer Society Updates Guideline for Cervical Cancer Screening
An updated cervical cancer screening guideline from the American Cancer Society released today has called for less—and more simplified—screening. The guideline was published by Fontham et al in CA: A Cancer Journal for Clinicians. The updated guideline recommends that individuals with a cervix...
Top Scientists Share Early Research on Intersection of COVID-19 and Cancer Care at AACR Virtual Meeting
The American Association for Cancer Research (AACR) Virtual Meeting: COVID-19 and Cancer took place from July 20 to 22, 2020, attracting top scientific minds from around the world to present preliminary research on the ever-evolving COVID-19 pandemic and its intersection with cancer care. In an...
Antoni Ribas, MD, PhD, on Racism and Racial Inequities in Cancer Research
Antoni Ribas, MD, PhD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, summarizes a special panel discussion on ways to eliminate cancer health disparities among racial and ethnic minorities. Increasing minority representation in clinical trials, thus ensuring...
Study Finds Lack of Parental Intent to Initiate and Complete HPV Vaccination in the United States
Study results documenting parental hesitancy to begin and complete their child's human papillomavirus (HPV) vaccine series were published by Sonawane et al in The Lancet Public Health. The Centers for Disease Control and Prevention recommends a two-dose HPV vaccination regimen for children if the...
Modeling Study Aims to Estimate the Effect of the COVID-19 Pandemic on Cancer Deaths in England
In a population-based modeling study reported in The Lancet Oncology, Maringe et al estimated that delays in diagnosis due to the COVID-19 pandemic could result in 3,291 to 3,621 additional deaths from breast, colorectal, esophageal, and lung cancers within 5 years. As stated by the investigators,...
Impact of Pregnancy After Breast Cancer in Women With Deleterious Germline BRCA Mutations
In a retrospective cohort study reported in the Journal of Clinical Oncology, Matteo Lambertini, MD, PhD, and colleagues found that pregnancy after breast cancer in women harboring deleterious germline BRCA mutations did not appear to be associated with worsened maternal prognosis or fetal...
Expert Point of View: Antoni Ribas, MD, PhD, and Richard T. Penson, MD
American Association for Cancer Research (AACR) President Antoni Ribas, MD, PhD, of UCLA School of Medicine, Jonsson Comprehensive Cancer Center, Los Angeles, commented on this study with statins and ovarian cancer: “This large study based on the records of more than 10,000 women over a 10-year...
Statin Use Linked to Improvement in Survival in Ovarian Cancer
Lipophilic statin use was associated with a reduced risk of dying of epithelial ovarian cancer in a large observational study. Compared with never users, women with epithelial ovarian cancer who were taking any type of statins had a reduced mortality of 40%, and those taking lipophilic statins had...
Expert Point of View: Michele Teng, PhD
Study discussant Michele Teng, PhD, of QIMR Berghofer Medical Research Institute, Brisbane, Australia, commented: “Cancer immunotherapy is a new pillar of cancer treatment. The aim is to improve the overall survival of patients with cancer, but there is room for improvement, and various...
Anti-TIGIT Antibody Plus Atezolizumab Move Forward in Advanced NSCLC
Tiragolumab, an anti-TIGIT antibody, plus the PD-L1 inhibitor atezolizumab exhibited early clinical activity and was tolerated in patients with advanced solid tumors, including those with metastatic non–small cell lung cancer (NSCLC) that was PD-L1–positive and untreated with prior checkpoint...
San Antonio Breast Cancer Symposium to Be Held Virtually
Today, the San Antonio Breast Cancer Symposium (SABCS) Executive Committee announced that the San Antonio Breast Cancer Symposium will take place in 2020. However, in response to the novel coronavirus (COVID-19) global pandemic, the Executive Committee has made the decision—out of necessity to...
Are Patients With a Longer-Established Diagnosis of Cancer at Higher Risk for More Severe Infection or Death From COVID-19?
According to research published by Russell et al in Frontiers in Oncology, patients with a longer-established diagnosis of cancer are at increased risk for more severe infection with COVID-19, as well as death from the virus. Patients of Asian ethnicity or who were receiving palliative treatment...
Expert Point of View: Philip A. Philip, MD, PhD, FRCP
The study’s invited discussant, Philip A. Philip, MD, PhD, FRCP, Professor of Oncology, Pharmacology, and Medicine and the Kathryn Cramer Endowed Chair in Cancer Research at Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, asked whether another triplet regimen was...
Neuroleptic Strategies for Improving Terminal Agitation in Patients With Cancer and Delirium
In a small single-center randomized trial reported in The Lancet Oncology, David Hui, MD, MS, MSc, and colleagues found that increasing haloperidol dose, rotating to chlorpromazine, and combining haloperidol and chlorpromazine each appeared to improve refractory agitation in patients with terminal...
First-Line Liposomal Irinotecan–Containing Regimen Studied in Advanced Pancreatic Cancer
In patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma, treatment with liposomal irinotecan plus fluorouracil (5-FU), leucovorin, and oxaliplatin (NALIRIFOX) resulted in a median progression-free survival of 9.2 months and a median overall survival of 12.6 months, ...
Jonathan W. Friedberg, MD, MMSc, Named Next Editor-in-Chief of the Journal of Clinical Oncology
Jonathan W. Friedberg, MD, MMSc, has been appointed as the next Editor-in-Chief of the Journal of Clinical Oncology (JCO), the flagship journal of ASCO. JCO publishes cutting-edge research on the diagnosis and treatment of patients with cancer and is one of the most highly cited oncology journals...
FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma
On July 24, the U.S. Food and Drug Administration (FDA) granted accelerated approval to brexucabtagene autoleucel (Tecartus), a CD19-directed genetically modified autologous T-cell immunotherapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma. “Tremendous...
Expert Point of View: David Sallman, MD
David Sallman, MD, Assistant Member of the Malignant Hematology Department at Moffitt Cancer Center and Research Institute, Tampa, Florida, commented on these findings for The ASCO Post. “Although the hypomethylating agent azacitidine represents a standard of care for higher-risk myelodysplastic...
Weathering the Storm: Personal Steps Toward Racial Equity in Oncology
“Of all the forms of inequality, injustice in health is the most shocking and the most inhumane because it often results in physical death. I see no alternative to direct action and creative nonviolence to raise the conscience of the nation.” —Martin Luther King, Jr, speaking before the Medical...
The Wake
The ASCO Post is pleased to reproduce installments of the “Art of Oncology,” as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
A Diagnosis of Advanced Lung Cancer Is No Longer a Death Sentence
In hindsight, the symptoms I began experiencing in the winter of 2013, including pains in my chest and shoulders and a persistent cough, should have rung loud alarm bells. However, having undergone a pancreatectomy and splenectomy to cure a history of mucinous cystic neoplasms of the pancreas 5...
Carolyn J. Anderson, PhD, Receives SNMMI 2020 Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science
Carolyn J. Anderson, PhD, has been named the 2020 recipient of the Paul C. Aebersold Award. Dr. Anderson is a Professor in the Departments of Medicine, Radiology, Bioengineering, Chemistry, and Pharmacology and Chemical Biology at the University of Pittsburgh in Pennsylvania. The award was...
Prominent Surgeon and Teacher LaSalle D. Leffall, Jr, MD, Promotes Hard Work and Education to Overcome Boundaries
LaSalle D. Leffall, Jr, MD, the Charles R. Drew Professor of Surgery at Howard University College of Medicine in Washington, DC, died on May 25, 2019, at the age of 89. The ASCO Post paid tribute to Dr. Leffall in its July 10, 2019, issue. Here, as part of our 10-Year Anniversary Series, we...
New, Updated ASCO eLearning Courses Put Oncology Education at Your Fingertips
As medical professionals increasingly turn to online learning opportunities in the midst of COVID-19 restrictions on travel and gatherings, ASCO eLearning delivers valuable, up-to-date clinical care courses for physicians, nurses, and advanced practitioners on a robust platform that can be easily...
ASCO’s CancerLinQ Launches the SmartLinQ™ QOPI® Certification Pathway, an Automated Solution for Quality Reporting for QOPI-Certified Practices
ASCO’s CancerLinQ® has launched the SmartLinQ™ QOPI® Certification Pathway, an application that empowers oncology practices to automate quality measure tracking and reporting for participation in ASCO’s Quality Oncology Practice Initiative (QOPI) Certification Program, a 3-year certification...
Cultivating Emotional Equanimity: Pause, Reflect, and Feel Meaning in Life, No Matter What
For many cultures that are addicted to the relentless quest to feel happy, perhaps as an unconscious attempt to bypass disavowed misery, grief is sort of a taboo, often pathologized and avoided by multiple means of denial. When we grieve, we’re told by well-meaning friends and relatives to “think...
Responding to Racism and Health Inequality as a Cancer Care Community
On June 3, 2020, ASCO President Lori J. Pierce, MD, FASTRO, FASCO, issued a statement on racism and health inequality. An excerpt from the statement follows: Months ago, when I defined a theme for my year as ASCO President, “Equity:Every Patient. Every Day. Everywhere,” I never imagined we would...
Palliative Care Resource for Your Patients From ASCO
Do your patients know that supportive care can help them manage the symptoms and side effects of cancer and treatment, regardless of their age, cancer type, or disease stage? Help your patients understand the benefits of palliative care and where to access these services with the ASCO Answers...
Lurbinectedin in Previously Treated Metastatic Small Cell Lung Cancer
On June 15, 2020, the alkylating drug lurbinectedin was granted accelerated approval for treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression during or after platinum-based chemotherapy.1,2 Supporting Efficacy Data Accelerated approval was based on...
Leading Organizations Release New Clinical Guideline on Advanced Prostate Cancer
The American Urological Association (AUA), American Society for Radiation Oncology (ASTRO), and Society of Urologic Oncology (SUO) recently announced a new clinical practice guideline for the diagnosis and treatment of advanced prostate cancer. Prostate cancer is one of the most commonly diagnosed...
Role of Rituximab in the Treatment of Children and Adolescents With Mature B-Cell Non-Hodgkin Lymphoma
Minard-Colin et al recently reported for the European Intergroup for Childhood Non-Hodgkin Lymphoma/Children’s Oncology Group (EICNHL/COG) a significant improvement in event-free survival among children and adolescents (aged 6 months to 18 years) with high-risk mature B-cell non-Hodgkin lymphoma...
If You Have Self-Doubt When Caring for a Loved One With Cancer
When taking care of a loved one with cancer, it’s natural to feel flooded with emotions—grief, guilt, and just plain old exhaustion. Feelings of inadequacy, doubt, or fear can sometimes pop up, too. Maybe you feel like you do not have the necessary skills to be a caregiver; maybe you feel like you...
New Guideline for Locally Advanced Esophageal Cancer Supports Multimodality Therapy and Multidisciplinary Treatment
ASCO has released a new guideline for the treatment of locally advanced esophageal cancer that will provide a context for the current standards of care, fill gaps in clinicians’ knowledge of therapy options, and help define future treatment.1 An expert panel developed the guideline based on 17...
Addition of Rituximab to Standard Chemotherapy Improves Event-Free and Overall Survival in Children With High-Risk, Mature B-Cell Non-Hodgkin Lymphoma
In a European Intergroup for Childhood Non-Hodgkin Lymphoma/Children’s Oncology Group phase III trial reported in The New England Journal of Medicine, Véronique Minard‑Colin, MD, PhD, of Gustave Roussy, Université Paris-Saclay, Villejuif, France, and colleagues found that the addition of rituximab...
